REFERENCE FILE
Tirzepatide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Activates GIP and GLP-1 receptors.
- Evidence
- Randomized trials.
- Limitations
- Check other products separately.
- Safety
- Severe or persistent gastrointestinal symptoms: contact a clinician.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Zepbound: weight management for eligible patients.
A SECOND LOOK
A question to carry into the reading
Choose a headline about tirzepatide and temporarily cover its conclusion. List the questions that would matter for judging the underlying claim, then inspect the report for each answer. Give separate rows to what was measured, what was compared, and what the headline chose to emphasize. Mark whether each answer is located, outside the report's stated scope, or still unresolved. Do not turn an empty row into a claim that something did not occur. Finally, uncover the headline and ask which rows it represents. This turns a memorable sentence into a map of its coverage, including the questions it leaves for the reader.
Questions to keep beside the page
- Which questions would I want answered before accepting this headline's conclusion?
- Which of those questions does the underlying report actually address?
- What would a fuller headline need to acknowledge about its scope?
Sources for this file
- ZEPBOUNDNLM · Checked
- Zepbound approvalFDA · Checked
FROM THE REFERENCE DESK